Valeant Weighs New Viramidine Dosing After Phase III Stumble
This article was originally published in The Pink Sheet Daily
Executive Summary
Prediction of a 2007 launch is unaltered by failure of first pivotal hepatitis C trial to meet one of two co-primary endpoints.